08:54 AM EDT, 04/04/2025 (MT Newswires) -- Health care stocks declined pre-bell Friday with the Health Care Select Sector SPDR Fund (XLV) down 0.5% and the iShares Biotechnology ETF (IBB) 1.6% lower recently.

Mesoblast (MESO) said it considers its allogeneic cellular therapies, including Ryoncil and Revascor, to be US-origin products that will not be subject to tariffs. Shares of Mesoblast fell by nearly 7% premarket.